Molecular Analysis for Personalised Therapy 2018: Industry Participation

The MAP congress is a one-of-a-kind meeting designed by a faculty of highly influential key opinion leaders to answer the need on how to integrate in daily practice the wealth of information coming from the analysis of tumour samples. 

Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and UNICANCER are the organisers of this annual forum where the understanding of the tumour microenvironment as well as the impact of macroevolution and their connection to treatment resistance is a significant field of discussion in personalised medicine. New models, technologies, the current treatment advances available and new findings of ongoing clinical trials are vital to understanding which molecular alterations should be the object of therapeutic targets in cancer treatment. 

Fast Facts: MAP 2018

  • Expecting over 400 participants
  • No parallel sessions
  • Possibility to host a satellite symposium
  • More than 28 key opinion leaders
  • Excellent networking opportunities 

How can I participate in the MAP 2018?

At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress. 

For sponsorship information and a prospectus please contact:

Jon Roberts
Head of Strategic Partnerships

We look forward to hearing from you!